Abstract：Objective: To explore the influence of intracoronary application of tirofiban on percutaneous coronary intervention (PCI)-related myocardial infarction (PMI) and clinical prognosis in treating acute coronary syndrome (ACS) after PCI. Methods: Totally 106 patients with ACS in the hospital from January 2020 to July 2024 were retrospectively selected and treated with PCI. According to whether tirofiban was injected into the coronary artery during surgery, the patients were divided into two groups, with 56 patients in the control group not injected with tirofiban, and 50 patients in the observation group given intracoronary injection of tirofiban. The thrombolysis in myocardial infarction (TIMI) blood flow grading status, myocardial injury markers [creatine kinase isoenzyme (CKMB), cardiac troponin I (cTnI)], postoperative ST segment recovery status, incidence of PMI, short-term cardiac function indicators [left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)] and incidence of major adverse cardiovascular events (MACE) were compared and analyzed in both groups. Results: The rate of TIMI blood flow grade 3 in the observation group after surgery was 96.00%, which was higher than 75.00% in the control group (P<0.05). The changes of CKMB and cTnI before and after surgery in the observation group with (11.87±1.48) μg/ml and (2.34±0.25) μg/ml were higher than (10.36±1.33) μg/ml and (1.76±0.33) μg/ml in the control group (P<0.05). At 90 minutes after surgery, the ST segment resolution of (64.28±14.39)% in the observation group was higher compared with (40.31±11.32)% in the control group (P<0.05). The incidence of PMI was lower in the observation group compared to the control group (0 vs. 7.69%) (P<0.05). The changes of LVEDD and LVEF in the observation group with (10.21±1.37) mm and (12.59±2.66)% before surgery and at 180 days after surgery were higher than the control group at (4.50±0.86) mm and (8.11±2.12)% (P<0.05). There was no statistical significance in the incidence of MACE between the groups (P>0.05). Conclusion: Intracoronary injection of tirofiban during PCI can enhance the postoperative TIMI blood flow grading of ACS patients, relieve the myocardial injury, further improve the ST segment recovery status, reduce the incidence of PMI, and improve the short-term cardiac function.
刘月宾, 刘红, 周金锋. 替罗非班联合PCI对急性冠状动脉综合征患者疗效PCI相关心肌梗死及预后的影响[J]. 河北医学, 2025, 31(6): 1043-1048.
LIU Yuebin, LIU Hong, ZHOU Jinfeng. Influence of Tirofiban Combined with PCI on Efficacy PCI-Related Myocardial Infarction and Prognosis in Patients with Acute Coronary Syndrome. HeBei Med, 2025, 31(6): 1043-1048.
[1] Damluji AA,Forman DE,Wang TY,et al.Management of acute coronary syndrome in the older adult population:a scientific statement from the American heart association[J].Circulation,2023,147(3):32-62. [2] de Gregorio C,Ferrazzo G,Koniari I,et al.Acute coronary syndrome from scombroid poisoning:a narrative review of case reports[J].Clin Toxicol (Phila),2022,60(1):1-9. [3] 万宇,左强.涤痰清心方联合针刺对痰热血瘀型急性冠脉综合征PCI术后病人炎性因子、心肌损伤标志物的影响[J].中西医结合心脑血管病杂志,2024,22(11):2018-2021. [4] 康永,陈明,王平.自拟宁心活血祛痰方结合阿司匹林对急性冠脉综合征经皮冠状动脉介入治疗术后血清亲环素A水平的影响[J].国际中医中药杂志,2023,45(10):1222-1226. [5] Sayama K,Hoshino M,Kanaji Y,et al.Prognostic implications of non-infarct-related territory unrecognized myocardial infarction in patients with non-ST-segment-elevation acute coronary syndrome[J].Cardiol,2023,82(6):433-440. [6] 闵敬亮,郭亚玲,周星辰,等.动脉内替罗非班治疗在急性前循环脑梗死机械取栓术中的临床研究[J].中国临床药理学杂志,2024,40(10):1395-1399. [7] Sabatine MS,Braunwald E.Thrombolysis in myocardial infarction (TIMI) study group:JACC focus seminar 2/8[J].Am Coll Cardiol,2021,77(22):2822-2845. [8] 马倩,董旭南.莱文征结合 TIMI 危险评分对急性胸痛患者的筛选急性冠脉综合征(ACS)的研究[J].新疆医科大学学报,2014(3):320-324. [9] Toda Kato E,Goto S.The TIMI study group's contributions to the advancement of cardiology-with focus on atherosclerotic cardiovascular disease[J].Atheroscler Thromb,2021,28(6):563-572. [10] Mateo-Rodriguez I,Danet A,Bolivar-Munoz J,et al.Gender differences,inequalities and biases in the management of acute coronary syndrome[J].Healthc Qual Res,2022,37(3):169-181. [11] 莫仡,曹洁,朱旭成,等.低剂量替罗非班用于急性颅内破裂动脉瘤支架置入结合弹簧圈栓塞治疗的有效性和安全性分析[J].中国脑血管病杂志,2024,21(9):587-594.
2025, Vol. 31 
冀公网安备13080202000786号